Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LILRB2


Brief Information

Name:Leukocyte immunoglobulin-like receptor subfamily B member 2
Target Synonym:Leukocyte immunoglobulin-like receptor 2,CD85 antigen-like family member D,Immunoglobulin-like transcript 4,ILT-4,Monocyte/macrophage immunoglobulin-like receptor 10,MIR-10,CD_antigen: CD85d,LILRB2,Leukocyte Immunoglobulin Like Receptor B2,Leucocyte Ig-Like Receptor B2,MIR10,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Member 2,Ig-Like Transcript 4,Myeloid Inhibitory Receptor 10,CD85d Antigen,ILT4,LIR2,CD85d,LIR-2,LIRB2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Immobilized Human LILRB2, Fc Tag (Cat. No. CDD-H5259) at 1 μg/mL (100 μL/well) can bind Anti-LILRB2 Antibody, Human IgG1 with a linear range of 1-2 ng/mL (QC tested).

LILRB2 MALS images

The purity of Biotinylated Human LILRB2 Protein, His,Avitag (Cat. No. LI2-H82E7) is more than 90% and the molecular weight of this protein is around 55-75 kDa verified by SEC-MALS.

Synonym Name



Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is also known as CD85 antigen-like family member D (CD85d), Immunoglobulin-like transcript 4 (ILT-4), Monocyte / macrophage immunoglobulin-like receptor 10 (MIR-10), which is a member of the the subfamily B class of LIR receptors. LILRB2 is receptor for class I MHC antigens. LILRB2 recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. LILRB2 competes with CD8A for binding to class I MHC antigens. LILRB2 / CD85d inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NGM-707 NGM-707 Phase 2 Clinical Merck & Co, Ngm Biopharmaceuticals Inc Ovarian Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Glioblastoma; Mesothelioma; Cholangiocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms Details
JTX-8064 JTX-8064 Phase 2 Clinical Jounce Therapeutics Inc Neoplasms Details
IO-108 IO-108 Phase 1 Clinical Solid tumours Details
MK-4830 MK-4830 Phase 2 Clinical Merck Sharp & Dohme Corp Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; uterine serous carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message